Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data.

Table 1 presents details on other demographic and baseline clinical characteristics for the overall study subjects based on BMI categories. Rivaroxaban prescribing trends among patients with thromboembolic diseases There was an increasing trend in rivaroxaban prescribing across the study period for the entire study cohort: 152 patients (3.3%) in 2015, 505 patients (10.9%) in 2016, 646 patients (13.9%) in 2017, 810 patients (17.5%) in 2018, 1183 patients (25.5%) in 2019, and 1342 patients (28.9%) in 2020 ( p <0.001) (Fig. 1 ).

also in 63,971 other papers

Within BMI categories, a similar increasing trend was observed in underweight, normal, and overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban prescribing in all obese classes.

also in 47,180 other papers